Category

• Pipeline1
• Products1

Organizations

• Bausch + Lomb64
• Alcon, Inc.43
• Eyes On Eyecare43
• American Optometric Association34
• Harrow28
• Glaukos26
• Regeneron22
• Topcon Healthcare22
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• FDA2
• Ocular Pain2
• Fda Approval1
• Glance Videos1
• Cataract Surgery1
• Eye Drop Solution1
• Eye Drops1
• Inflammation1
• New Drug Application1
• Products1

• Organizations: AimMax Therapeutics✕

Clear all

Products

FDA approves clobetasol propionate suspension for postop inflammation and pain

Developed by Formosa with exclusive U.S rights owned by Eyenovia, the novel ophthalmic APP13007 is expected to launch mid-2024.

Pipeline

Formosa and AimMax submit joint NDA for ocular pain and inflammation

Novel ophthalmic APP13007 is designed to provide eye comfort and enhanced drug penetration into ocular tissues.